Quotient Clinical’s Chief Scientific Officer awarded honorary professorship at the University of Nottingham
Quotient Clinical, the Translational Pharmaceutics® Company, has announced that Dr Peter Scholes, its Chief Scientific Officer, has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham. The award recognizes distinguished individuals who have strengthened links between the University and practical experience in business and industry, through seminars, lectures and research collaborations.
Quotient Clinical announces expansion of pharmaceutical sciences capacity
Quotient Clinical, the Translational Pharmaceutics® Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories. The new laboratories, based within the company’s existing Nottingham facility, were commissioned in response to an increasing […]
Quotient Clinical begins prostate cancer project for Druggability Technologies
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the initiation of a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate, a marketed drug prescribed in combination with prednisone to patients suffering from metastatic prostate cancer.
Quotient Clinical CEO Mark Egerton Wins EY Entrepreneur of the Year 2015 Award
Quotient Clinical has announced that CEO Mark Egerton has received the EY Entrepreneur of the Year® 2015 Award in the healthcare category for the Midlands region.
Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers.
Quotient Clinical reports another successful year of record growth
Quotient Clinical, the Translational Pharmaceutics® Company, announces another strong year of progress and growth. Quotient’s Translational Pharmaceutics platform has been adopted by more than 30 new customers – ranging from top 20 pharma companies to emerging biotech organizations – contributing to a year-on-year increase in revenue of 24%, with similar growth levels anticipated in the next 12 months.